Concurrent Chemotherapy and Short Course Radiotherapy in Patients with Stage IIIA to IIIB Non-small Cell Lung Cancer Not Eligible for Radical Treatment: Results of a Randomized Phase II Study  by Nawrocki, Sergiusz et al.
ORIGINAL ARTICLE
Concurrent Chemotherapy and Short Course Radiotherapy
in Patients with Stage IIIA to IIIB Non-small Cell Lung
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Introduction: The optimal treatment for patients with stage IIIA to
IIIB non-small cell lung cancer (NSCLC) not eligible for surgery
and definitive chemoradiotherapy is unknown. The aim of this
study was to evaluate concurrent chemotherapy and palliative
radiotherapy.
Methods: Patients with stage IIIA to IIIB NSCLC with tumor 8
cm and/or forced expiratory volume 40%, performance status 0 to
2, and tumor-related chest symptoms were randomly assigned to arm
A: radiotherapy alone (30 Gy/10 fractions) or arm B: chemoradio-
therapy (two cycles of cisplatin and vinorelbine followed by radio-
therapy together with third cycle). Primary end point was response
rate, the power of the study was 90%, and the significance level was
p  0.1.
Results: A total of 99 patients were eligible for response, overall
survival, and progression-free survival evaluation. Median age was
66 years (45–78 years). Response rate was 27% versus 53%, p 
0.08; median overall survival was 9.0 versus 12.9 months, p 
0.0342; and median progression-free survival was 4.7 versus 7.3
months, p 0.046, in arm A versus arm B, respectively. There were
no deaths during treatment in arm A and six deaths in arm B; no
hematological G3 to G4 toxicities in arm A and 14 toxicities in arm
B. Symptom control was high and similar in both arms.
Conclusions: Upfront chemotherapy combined with palliative ra-
diotherapy (30 Gy) is a promising treatment option in the subpopu-
lation of patients with stage IIIA to IIIB NSCLC not amenable for
definitive chemoradiotherapy and deserves further investigation.
Key Words: Locally advanced non-small cell lung cancer, Pallia-
tive chemoradiotherapy, Palliative radiotherapy.
(J Thorac Oncol. 2010;5: 1255–1262)
Most patients with non-small cell lung cancer (NSCLC)are diagnosed with the disease in the advanced stage
and are not eligible for surgery. For patients with unresect-
able stage IIIA and a subset of stage IIIB disease (no malig-
nant pleural effusion), combined modality of treatment (che-
motherapy and radiotherapy) is associated with better
outcome than radiotherapy alone.1,2 Concurrent radiotherapy
and chemotherapy is better than sequential approach, however,
at the expense of significant toxicity.3 Unfortunately, many
patients in stage IIIA to IIIB are not candidates for definitive
chemoradiotherapy because of poor performance status (PS),
large tumor, poor pulmonary function, and comorbidities. Re-
cent prospective analysis showed that most of the potential
patients in stage III (60%) are not eligible for definitive
chemoradiotherapy.4 These patients are treated either with pal-
liative radiotherapy or palliative chemotherapy, and there is lack
of randomized trials comparing these two modalities. Moreover,
to date, there have been no randomized studies published with
“palliative chemoradiotherapy” for this group of patients.
In patients with large tumor, the probability of both
local and distant control is low. Poor pulmonary function is
also an important factor excluding patients from definitive
combined chemoradiotherapy because of high pulmonary
toxicity of definitive radiotherapy.
The aim of this study was to evaluate palliative che-
moradiotherapy in patients with stage IIIA to IIIB NSCLC
not qualified for radical chemoradiotherapy because of large
tumor and/or poor pulmonary reserve in randomized phase II
study. Treatment consisted of two chemotherapy cycles
followed by third course concurrently with short radiother-
apy (30 Gy). As a control arm, we have chosen short
radiotherapy alone, which used to be a palliative treatment
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Patients with histologically or cytologically confirmed
diagnosis of NSCLC, inoperable patients with stage IIIA or
IIIB, PS 0 to 2 (World Health Organization), forced expira-
tory volume (FEV1)40%, and/or tumor (primary tumor and
involved lymph nodes) 8 cm in longest diameter were
included in this study. Other eligibility criteria were age 18
years or older, absolute granulocyte count 1500/l, platelet
count 100,000/l, hemoglobin 10.0 g/dl, and serum cre-
atinine, alanine aminotransferase, and aspartate transaminase
less than 1.5 institutional upper limit of normal. Patients must
not have received any prior systemic chemotherapy or radiation
therapy for NSCLC. Patients must not have obstructive pneu-
monia or other serious infection at the time of enrollment or
other serious underlying medical condition, which would impair
the ability of the patient to receive protocol treatment. Patients
who have clinically significant pleural effusion were excluded
from the study. All patients have signed written informed con-
sent, and the study was approved by bioethical committees of
the participating institutions.
Treatment
Patients were randomly assigned to radiotherapy alone
(arm A) or chemoradiotherapy (arm B). In arm A, patients
received 30 Gy/10 fractions. In arm B, patients received two
cycles of chemotherapy (cisplatin 80 mg/m2 on day 1, Na-
velbine 25 mg/m2 on days 1 and 8). In case of clinical
response (no progression by Response Evaluation Criteria in
Solid Tumors [RECIST]), radiotherapy as mentioned earlier
was given together with third cycle (starting at the first day of
chemotherapy). In case of excellent clinical response after
two chemotherapy cycles, patients could be irradiated with
radical intent (66 Gy/33 fractions) of protocol, but there were
no such patients.
Radiotherapy was administered using linacs with 6 MV
photon energy. Three-dimensional conformal planning was
used. Clinical tumor volume included the primary tumor
(tumor and involved lymph nodes), the ipsilateral hilar and
subcarinal lymph nodes, and the mediastinum 2 cm above
and below the involved lymph nodes. Planned tumor volume
included the clinical tumor volume plus an isotropic margin
of 1.0 cm. Dose prescription used the International Commis-
sion for Radiation Units Report 50 as reference point.
Response and Toxicity Evaluation
Prestudy assessment included medical history, physical
examination, bronchoscopy, computed tomography (CT) of
chest with upper abdomen, complete blood count with differen-
tial, platelet count, blood biochemistry, and spirometry. Com-
plete blood counts and blood biochemistry were repeated before
every chemotherapy administration within 48 hours. Toxicity
was graded according to common toxicity criteria (version 2).
Tumor response was evaluated by CT before the third
cycle of chemotherapy and 4 weeks after completing radio-
therapy (RECIST) by nonblinded investigators. Each of the
four symptoms (dyspnoea, pain, cough, and hemoptysis) was
evaluated in a 4-grade scale (0, no symptoms; 1, mild, 2,
moderate, and 3, severe). Follow-up visits were scheduled
every 3 months during the first year and then every 6 months.
CT of the chest was scheduled every 6 months or at clinical
progression.
Statistical Methods
The trial was designed as randomized, two-center (Ol-
sztyn, Warsaw), phase II study. The trial was designed to
obtain efficacy and toxicity data in experimental arm (che-
moradiotherapy) in comparison with radiotherapy in the same
population of patients chosen with specific selection criteria.
Randomization was performed by dedicated computer pro-
gram with stratification according to (1) PS (0–1 versus 2),
(2) clinical stage (IIIA versus IIIB), and (3) site (Olsztyn
versus Warsaw).
The primary end point of the trial was response rate
(RR). Sample size was determined with Simon optimal two-
stage study design to distinguish between RR 40% and 60%
after the completion of therapy with the overall type I and II
error rates 10%, which is acceptable for phase II studies.5–7
Eighteen patients were to be accrued in the first stage and up
to 46 patients in the second stage per study arm. At least 7 of
18 responses were required (arm B) in the first phase to
continue the study. The final sample size was determined as
50 patients per study arm with a total of 100 patients in both
arms to account for dropouts. Secondary end points were (1)
toxicity, (2) overall survival (OS), (3) progression-free sur-
vival (PFS), and (4) symptoms control. OS and PFS were
estimated by Kaplan-Meier method and were compared with
log-rank test; however, the trial was not powered adequately
to detect even large differences in OS or PFS. Hazard ratio
(HR) was determined using the Cox proportional hazards
regression model. All randomized patients who met eligibil-
ity criteria were included in the RR, OS, and PFS analysis
(intention-to-treat [ITT] population). The per protocol anal-
ysis of RR was evaluated in patients who completed at least
two cycles of chemotherapy in arm B and completed radio-
therapy in arm A (2 test). Toxicity was assessed in patients
who started chemotherapy or radiotherapy. Symptom control
was assessed at the study entry and 4 weeks after completion of
therapy. The differences between two arms were assessed using
2 test for categorical variables. Statistical analysis was per-
formed in Statistica 6.0 software (StatSoft Inc., Tulsa, OK).
RESULTS
Patients’ Characteristics
Between August 2004 and September 2006, 105 pa-
tients were randomized (87 in Olsztyn and 18 in Warsaw).
Ninety-nine patients were included in ITT analysis for RR,
OS, and PFS (48 patients in arm A and 51 patients in arm B).
Study flow is shown in Figure 1. The clinical characteristics
of patients are summarized in Table 1. Overall, the median
age was 66 years (range, 45–78 years); 91 patients (92%)
were men; predominant histology was squamous carcinoma
(73 cases; 74%); 72 patients (73%) had stage IIIB NSCLC;
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and 73 patients (74%) were in PS 0 to 1. Most of the patients
(80%) were not eligible for radical chemoradiotherapy be-
cause of large tumor, whereas 20% were not eligible because
of FEV1 40%. Median follow-up was 41 months (range,
27–52 months). Both groups were well balanced for all
characteristics.
Treatment Delivery and Toxicity
Of 51 patients in arm B, 35 patients (69%) received all
three cycles of chemotherapy, 42 patients (82%) received a
minimum of two cycles, 7 patients (14%) received only one
cycle, and 2 patients did not receive chemotherapy because of
rapid progression. In 28 of 49 patients (57%), there were
neither delays nor reductions of dose. Delays were necessary
in 11 patients and reductions in 10 patients. There were six
early deaths in arm B, five during the treatment and one death
just after the completion of chemoradiotherapy. Two of these
deaths were possibly chemotherapy related (one patient de-
veloped pancytopenia and diarrhea and the second developed
brain hemorrhage). Another three deaths were probably be-
cause of progressive disease, and one patient died because of
an unknown reason. Clinical characteristics of these six
patients are presented in Table 2. There were no deaths
during radiotherapy in arm A. Treatment-related toxicity is
summarized in Table 3. In most cases, toxicities were ob-
served in arm B; however, statistically significant difference
between arms was observed only in the case of neutropenia.
Response to Treatment
Of 99 randomized patients, 83 patients were eligible for
RR evaluation. The reasons of noneligibility for response eval-
uation are provided in study flow chart (Figure 1). In ITT
population, there were 13 (27%) responses in arm A (1 complete
response and 12 partial responses) and 27 (53%) responses in
arm B (4 complete responses and 23 partial responses). There
were 3 progressions in both arms and 28 stabilization of disease
in arm A and 9 in arm B. In ITT analysis, the difference in RR
was not statistically significant (p  0.08) using commonly
accepted significance level of 0.05; however, the primary end
point was met according to prespecified type I error probability
of 0.10. In per protocol analysis, there were 27 responses of 42
patients in arm B (64%) and 13 responses of 47 patients in arm
A (28%) (p  0.032).
Survival and Time to Progression
All 99 randomized patients were included in OS and
PFS analysis with median follow-up of 41 months (range,
27–52 months). At the time of final analysis (December
Randomized; 
n=105
Eligible for ITT analysis of overall survival, 
progression free survival and response rate; 
n=99
Eligible for toxicity  
n=96
Evaluable for response 
n=83
n=6 exluded before starting allocated intervention 
- 2 patients: inclusion criteria not met: (1) metastasis in the second lung; (2) large 
inflammatory lesion in lung with necrosis and air bubbles 
- 3 patients: consent withdrawal  
- 1 patient: did not come for treatment, lost from observation 
n=3 did not start treatment because of progression or comorbidities 
- 2 patients: disease progression 
- 1 patient: brain stroke 
n=13 did not have response evaluation CT due to 
- 6 patients: early death; see Table 3. 
- 7 patients: progression, comorbidities 
FIGURE 1. Study flow.
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2008), 7 of 51 patients (14%) in arm B and 3 of 48 patients
(6%) in arm A were alive. There were no significant differ-
ences in distribution of different causes of death (Table 4).
OS was significantly longer in arm B than in arm A with median
of 12.9 and 9.0 months, respectively (p  0.034, log-rank;
HR  0.62, 95% confidence interval 0.40–0.95). One- and
2-year OS probabilities were 57% and 24% in arm B, whereas
it was 25% and 6% in arm A, respectively (Figure 2).
PFS was significantly longer in arm B than in arm A with
median of 7.3 and 4.7 months, respectively (p  0.046, log-
rank; HR 0.65, 95% confidence interval 0.43–0.99). One- and
2-year PFS probabilities were 20% and 14% in arm B, whereas
it was 8% and 4% in arm A, respectively (Figure 3).
In arm A, on clinical or radiologic progression, chemo-
therapy was planned, however this was not specified in the
study protocol. Only a minority of patients (13) received
chemotherapy, most patients were not eligible for chemother-
apy because of poor PS. Second-line chemotherapy was
given to 15 patients in arm B.












Male 45 (94) 46 (90)
Female 3 (6) 5 (10)
PS (WHO) (%) NS
0–1 36 (75) 37 (73)
2 12 (25) 14 (27)
Stage (%) NS
IIIA 11 (23) 16 (31)
IIIB 37 (77) 35 (69)
TNM (%) NS
T3 N0–1 1 (2) 0
T1–3 N2 10 (21) 18 (35)
T1–3 N3 8 (17) 7 (14)
T4 N0–2 19 (40) 18 (35)





Squamous carcinoma 36 (75) 37 (73)
Adenocarcinoma 6 (13) 8 (16)
Other 5 (10) 4 (8)
Not specified 1 (2) 2 (4)
Site (%) NS
Warsaw 9 (19) 9 (18)
Olsztyn 39 (81) 42 (82)
TNM, tumor, node, metastasis; WHO, World Health Organization; PS, perfor-
mance status; FEV, forced expiratory volume; NS, nonsignificant.
TABLE 2. Clinical Characteristics of Patients Who Died During Treatment







Diameter (cm) Cause of Death Timing of Death
1 64 M Squamous T3N2 1 63 11.6 Pancytopenia, gastrointestinal
toxicity
After first chemotherapy cycle
2 76 M Squamous T2N2 0 69 8.0 Not known After first chemotherapy cycle
3 72 M Squamous T4N3 0 93 8.5 Pulmonary embolism After second chemotherapy cycle
4 61 M Squamous T3N3 0 65 10.0 Brain hemorrhage After second chemotherapy cycle
5 72 M Squamous T4N3 0 51 8.0 Pulmonary hemorrhage During chemoradiotherapy
6 59 M Adenocarcinoma T4N3 0 77 10.2 Pulmonary hemorrhage After chemoradiotherapy
TNM, tumor, node, metastasis; PS, performance status; FEV, forced expiratory volume.





(n  48) (%)
Chemoradiotherapy
(Arm B)
(n  51) (%) p
Neutropenia 0 11 (22) 0.002
Anemia 0 2 (4) NS
Thrombocytopenia 0 1 (2) NS
Esophagitis 0 1 (2) NS
Renal toxicity 0 1 (2) NS
Cardiotoxicity 1 (2) 2 (4) NS
Pulmonary 2 (4) 3 (6) NS
Cerebral stroke 1 (2) 2 (4) NS
Gastrointestinal 0 1 (2) NS
Mental 0 1 (2) NS
Early deaths 0 6 (12) 0.018
NS, nonsignificant.




(n  45) (%)
Chemoradiotherapy
(Arm B)
(n  44) (%)
Toxicity 0 2 (5)
Local progression (chest) 19 (42) 20 (45)
Metastases 16 (36) 11 (25)
Metastases and local 3 (7) 5 (11)
Not known 7 (16) 6 (14)
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Control of Symptoms
Chest-related symptoms were scored in 46 patients
(94%) before and in 42 patients (86%) after treatment in arm
A and in 47 patients (94%) before and in 34 patients (68%)
after therapy in arm B (Table 5). In general, symptom control
was satisfactory and similar in both arms. Sixty-seven percent
of patients were pain free after radiotherapy and 85% of
patients after chemoradiotherapy. Only 2% of patients in arm
A and no patient in arm B had moderate or severe pain after
therapy. Seventy-six percent of patients were cough free after
radiotherapy and 82% of patients after chemoradiotherapy.
Only 2% of patients in arm A and 6% of patients in arm B had
moderate or severe cough after therapy. Ninety-five percent
of patients did not report hemoptysis after radiotherapy and
FIGURE 2. Progression-free sur-
vival for patients treated with ra-
diotherapy (arm A, n  48) versus
chemotherapy (arm B, n  51).
HR, hazard ratio; CI, confidence
interval.
FIGURE 3. Overall survival for pa-
tients treated with radiotherapy
(arm A, n  48) versus chemother-
apy (arm B, n  51). HR, hazard
ratio; CI, confidence interval.
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100% of assessed patients after chemoradiotherapy. No pa-
tient in both arms reported moderate or severe hemoptysis
after treatment. Sixty percent of patients had no dyspnoea
after radiotherapy and 70% of patients after chemoradiother-
apy. Only 2% of patients in arm A and 9% of patients in arm
B had moderate or severe dyspnoea after therapy. Because
the symptom control was high in both arms and clinically the
differences are not important, a statistical comparison be-
tween arms was not performed.
DISCUSSION
The aim of this trial was to evaluate “palliative chemo-
radiotherapy” in patients with stage IIIA to IIIB NSCLC not
eligible for radical radiotherapy. Usually, only two categories
of patients with NSCLC are recognized: (1) eligible for
definitive treatment and (2) eligible for palliative treatment.
This “black and white” approach is too simplistic. A third
category of patients have been defined who deserve their own
treatment approach. The authors of this article decided to
treat these “gray zone” patients with novel chemoradiother-
apy regimen.
Definitive chemoradiotherapy is a treatment of choice
in patients with stage IIIA to IIIB inoperable lung cancer in
good PS with minimal weight loss and adequate pulmonary
reserve. The meta-analyses demonstrated the benefit of che-
motherapy added to definitive radiotherapy (4% in 2-year OS
and 2% in 5-year OS).1,2 Concurrent chemoradiotherapy is
superior to sequential approach (14% reduction in risk of
death at 2 years).3 Unfortunately, in daily practice, many
patients in stage IIIA to IIIB are not eligible for definitive
chemoradiotherapy because of inadequate PS, comorbidities,
advanced age, too large tumor, rapid weight loss, and inad-
equate pulmonary function. Radiotherapy can effectively pal-
liate the symptoms (chest pain, hemoptysis, cough, dyspnea,
and dysphagia) of patients with poor prognosis.8–10 However,
patients with locally advanced NSCLC not eligible for radical
chemoradiotherapy but with relatively good PS, probably,
could be treated more aggressively than with palliative radio-
therapy alone. Controversy remains about whether long term
and high doses of radiotherapy provide better results than
short-course schedules.11,12 Recent reviews have shown that
fractionated radiotherapy with higher total dose (35 Gy10
versus lower biologically equivalent dose radiotherapy regi-
mens, considering /  10) is better than single fraction or
short radiotherapy in terms of survival and symptom con-
trol.13 In this study, higher dose palliative radiotherapy (30
Gy/10 fractions) was chosen for both study arms. In the
experimental arm, treatment consisted of two cycles of
induction chemotherapy followed by radiotherapy together
with the third cycle. Chemotherapy consisted of cisplatin
and vinorelbine as a radiosensitizing regimen according to
the cancer and leukemia group B (CALGB) 9431 data.14
Patients included in this trial had locally advanced large
tumors (8 cm) and/or poor pulmonary reserve (FEV1
40%). This is a specific population of patients with stage
IIIA to IIIB lung cancer with poor local control and high risk
of pulmonary toxicity. The strongest prognostic factors for
the development of lung toxicity are poor FEV1 and mean
TABLE 5. Symptoms Control
Symptoms
Radiotherapy (Arm A) Chemoradiotherapy (Arm B)
Before RT After RT
2 Test
Before CRT After CRT
2 Testn  46 % n  42 % n  47 % n  34 %
Pain
0 22 48 28 67 NS 25/46 54 29 85 NS
1 12 26 13 31 NS 16/46 35 5 15 NS
2 8 17 1 2 p  0.56 4/46 9 0 0 p  0.09
3 4 9 0 0 p  0.60 1/46 2 0 0 NS
Cough
0 16 35 32 76 p  0.34 15 32 28 82 p  0.014
1 20 43 9 22 NS 25 53 4 12 p  0.006
2 9 20 1 2 p  0.022 6 13 2 6 NS
3 1 2 0 0 NS 1 2 0 0 NS
Haemoptysis
0 38 83 40 95 NS 33 70 34 100 NS
1 8 17 2 5 p  0.094 12 26 0 0 p  0.005
2 0 0 0 0 NS 2 4 0 0 NS
3 0 0 0 0 NS 0 0 0 0 NS
Dyspnoea
0 17 37 25 60 NS 21 45 24 70 NS
1 19 41 16 38 NS 19 40 7 21 NS
2 10 22 0 0 p  0.004 7 15 3 9 NS
3 0 0 1 2 NS 0 0 0 0 NS
RT, radiotherapy; CRT, chemoradiotherapy; NS, nonsignificant.
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lung dose, which is defined as the average dose for the total
lung volume.15,16
These specific selection criteria of this trial make com-
parisons with other published data difficult and of limited
relevance. Specific population that was represented by the
patients of this study was partly included in both definitive
and palliative trials. In the definitive chemoradiotherapy tri-
als, such patients probably constitute the category of patients
with poor treatment results, whereas in the palliative radio-
therapy trials, they are likely to be patients with better than
average outcomes. Local control rates and survival figures of
patients treated with short “palliative chemoradiotherapy” in
this trial fall in the range of definitive sequential chemora-
diotherapy rather than palliative treatment (RR 53%; median
OS 12.9 months, ITT analysis). Nestle et al.17 compared two
radiotherapy regimens (60 Gy/30 fractions with accelerated
32 Gy/16 fractions) in patients not eligible for definitive
chemoradiotherapy based, however, predominantly on PS.
They did not find differences in survival and palliation
between arms (OS 8.4 months, 2-year survival 9%). These
figures are very comparable with arm A of this trial (OS 9.0
months, 2-year survival 6%). Zatloukal et al.18 tested the
same chemotherapy regimen (up to four cycles) with radical
radiotherapy comparing concurrent with sequential approach
in a randomized trial. The median OS in concurrent arm was
16.6 months and in the sequential arm 12.9 months, which is
the same as the OS in arm B of this trial. In this study,
patients treated with chemoradiotherapy demonstrated better
OS than those treated with radiotherapy alone (2-year OS
24% versus 6%, respectively), and it is comparable with OS
of patients after radical sequential chemoradiotherapy (2-year
OS 30%).19,20 Two-year OS reported in several trials with
palliative radiotherapy alone is 6 to 8%.13,21
This trial confirms that combined palliative treatment is
also promising in terms of local tumor control and delays
progression. Zatloukal et al.18 comparing radical concurrent
with sequential chemoradiotherapy in local advanced NSCLC
showed a RR of 80% in concurrent arm and 47% in sequen-
tial arm. In this study, RR in arm B (53%) was numerically
slightly higher than in Zatloukal’s sequential arm.
Most of the patients (94%) demonstrated tumor-related
symptoms before study treatment; therefore, palliative radio-
therapy as upfront treatment was chosen for control arm in
the study. This study turned out that only minority (27%) of
patients treated with radiotherapy alone were treated with
chemotherapy on progression. The treatment on progression
was not specified by the study protocol and was left to the
decision of the treating physician. It turned out that most
patients treated with palliative radiotherapy did not receive
chemotherapy at all because of rapid progression and poor
PS. Radiotherapy alone in this group of patients might be a
suboptimal treatment in terms of survival, and better results
of our experimental arm might have been due to early
commencement of systemic treatment.
Vinorelbine and cisplatin seem to be suitable regimen
for concurrent treatment not only for its radiosensitizing
potential and systemic effect but also because of acceptable
toxicity. Six early deaths were observed in arm B compared
with no early deaths in arm A. Most of these early deaths
(four of six) should not be attributed to toxicity of combined
chemoradiotherapy because they occurred before starting the
radiotherapy. Analysis of this small cohort of patients shows
one common feature—large tumor. In general, most toxicities
were observed in arm B; however, statistically significant
difference between arms was seen only in the case of neu-
tropenia. Toxicity of combined treatment is acceptable, but
caution is advisable in patients with very large tumors.
In conclusion, this “palliative chemoradiotherapy” reg-
imen consisting of three cycles of cisplatin-vinorelbine com-
bined with higher dose palliative radiotherapy (30 Gy/10
fractions given concurrently with the third chemotherapy
course) is a promising treatment option in terms of RR, OS,
and PFS in the subpopulation with stage IIIA to IIIB NSCLC
not amenable for definitive chemoradiotherapy and needs
further investigation. Relatively high toxicity in patients with
large tumors should be taken into account when considering
this approach. Palliative radiotherapy alone seems to be a
suboptimal treatment in these patients in terms of RR, PFS, or
OS; however, early symptom control was similar. The “gray
zone” subpopulation of patients with NSCLC needs its own
treatment. Furthermore, clinical trials considering this subset
of patients are needed.
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